Femtobiomed, Inc. engages in the development of pharmaceutical products. Its services include intracellular delivery for cell therapy. The company was founded on July 8, 2011 and is headquartered in Seongnam-si, South Korea.
The current price of 327610 is 8260 KRW — it has decreased by 0.60% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange FEMTOBIOMED stocks are traded under the ticker 327610.
327610 stock is 5.61% volatile and has beta coefficient of 2.09. Check out the list of the most volatile stocks — is FEMTOBIOMED there?
Yes, you can track FEMTOBIOMED financials in yearly and quarterly reports right on TradingView.
327610 stock has fallen by 6.14% compared to the previous week, the month change is a 8.22% fall, over the last year FEMTOBIOMED has showed a 3.90% increase.
Today FEMTOBIOMED has the market capitalization of 69.81 B, it has decreased by 0.80% over the last week.
No, 327610 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 327610 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FEMTOBIOMED stock right from TradingView charts — choose your broker and connect to your account.
327610 reached its all-time high on Aug 4, 2021 with the price of 24900 KRW, and its all-time low was 4600 KRW and was reached on Jan 5, 2024. See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 12.00 employees. See our rating of the largest employees — is FEMTOBIOMED on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So FEMTOBIOMED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating FEMTOBIOMED stock shows the sell signal. See more of FEMTOBIOMED technicals for a more comprehensive analysis. If you're still not sure, try looking for inspiration in our curated watchlists.